1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial
Titel:
1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial
Auteur:
Saura, C. Vivancos, A. Matito, J. Wildiers, H. Brufsky, A.M. Oliveira, M. Waters, S. Hurvitz, S.A. Moy, B. Kim, S-B. Gradishar, W.J. Queiroz, G.S. Cronemberger, E. Bebchuk, J. Keyvanjah, K. Lalani, A.S. Eli, L.D. Delaloge, S.